From Nantes to Global Dominance: Eurofins Scientific Secures €400 Million to Accelerate Innovation and Expansion

Eurofins Scientific is thrilled to announce a remarkable funding milestone, having successfully raised €400,000,000 to further fuel its mission of advancing quality and reliability in analytical testing on a global scale. Founded in 1987 with its first laboratory in Nantes, France, Eurofins has rapidly evolved into a powerhouse within the industry, now employing approximately 63,000 dedicated professionals across a network of independent companies operating in 60 countries and more than 950 laboratories. This significant capital infusion not only underscores the market’s confidence in Eurofins' innovative approach and sustained growth trajectory but also reaffirms its position as one of the leading emerging players in specialized clinical diagnostics testing and analytical services. Ever since its initial public offering on the French stock exchange in 1997, Eurofins has consistently broken new ground and set industry benchmarks by performing over 450 million tests annually and offering a robust portfolio of over 200,000 analytical methods. The funds will be strategically directed towards expanding the company’s infrastructure, accelerating research and development efforts, and integrating next-generation technologies to enhance testing capabilities further. Additionally, key investments will be made in the development of innovative clinical diagnostic services and the expansion of its extensive network of testing laboratories. As Eurofins continues to evolve in a fast-paced, dynamic market, this announcement marks a pivotal step towards broadening their global reach, elevating service quality, and reinforcing their commitment to ensuring the safety, identity, and authenticity of an ever-growing range of biological substances and products.